More Resources

The Bonneville Power Administration (BPA) announces its environmental findings on the Palisades-Goshen Transmission Line Reconstruction Project. The project involves rebuilding the existing Palisades-Goshen 115-kilovolt (kV) transmission line, which extends from Palisades Dam in eastern Idaho approximately 52 miles west to the Goshen Substation south of Idaho Falls, Idaho.

Palisades - Goshen Transmission Line Reconstruction Project

Solar Energy Development in Six Southwestern States

The INL Site EM CAB supports DOE's decision to accept transuranic waste to be treated at the Advanced Mixed Waste Treatment Project (AMWTP)

This is a request by NORMANN, RANDY A. for a DOE waiver of domestic and foreign patent rights under agreement DE-AC04-94AL85000

This is a request by NORMANN, RANDY A. for a DOE waiver of domestic and foreign patent rights under agreement DE-AC04-94AL85000

On May 28-29, 2008, the first ieRoadmap Workshop was held to assist the energy sector in assessing alignment of current industry projects with the goals outlined in the Roadmap to Secure Control Systems in the Energy Sector.

On May 28-29, 2008, the first ieRoadmap Workshop was held to assist the energy sector in assessing alignment of current industry projects with the goals outlined in the Roadmap to Secure Control Systems in the Energy Sector.

As part of its program to produce isotopes for medical, research and industrial purposes. the Departnient of Energy (Department) has used its unique nuclear facilities to produce thorium-229 isotopes f'rom its inventory of uranium-233. Thorium-229 is used to create actiniurn-225 and its progeny isotope, bismuth-213. Both actinium and bismuth are extreniely rare isotopes that are now being used in clinical trials and cancer research at organi~ationsu ch as the Memorial Sloan-Kettering Cancer Center in New York. Early research results have been promising, showing improved cancer survivability rates in test populations. Consistent with these research results, a 2001 Departmental Report to Congress underscored the importance of maintaining a supply of these isotopes to support promising medical research and treatment. Specifically, the report stated that "the supply of actinium-225lbismuth-213 available as uranium-233 decay products will be inadequate if therapeutic applications for leukemia become even moderately successful and will become woefully inadequate if successfully applied to other types of cancer including prostate, breast. lymphomas, and various forms of brain cancer."

Meeting Medical and Research Needs for Isotopes Derived from Uranium-233